Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients - 28/08/11
Doi : 10.1016/S0002-9149(03)00162-0
Tareq S Harb, MD a, Wojciech Zareba, MD, PhD a, ⁎ 
, Arthur J Moss, MD a, Paul M Ridker, MD e, Nader Rifai, PhD d, Victor J Marder, MD c, Luc Miller-Watelet, PhD b
, Arthur J Moss, MD a, Paul M Ridker, MD e, Nader Rifai, PhD d, Victor J Marder, MD c, Luc Miller-Watelet, PhD bTHROMBO Investigators
a Cardiology Unit, Department of Medicine, USA
b Department of Biostatistics, University of Rochester Medical Center, Rochester, New York, USA
c Vascular Medicine Program, Orthopaedic Hospital, UCLA School of Medicine, Los Angeles, California, USA
d Departments of Laboratory Medicine and Pathology, Children’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
e Center for Cardiovascular Disease Prevention and Division of Cardiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USAThis study was supported by grants 5R01 HL-48259 and HL-30616 from the National Institutes of Health, Bethesda, Maryland.
*Dr. Zareba’s address is: Heart Research Follow-Up Program, University of Rochester Medical Center, Box 653, Rochester, New York , USA14642.
© 2003
Excerpta Medica Inc. Tous droits réservés.
Vol 91 - N° 9
P. 1120-1123 - mai 2003 Retour au numéro
Article précédent
- Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease
- Wright B Lauten, Qamar A Khan, Sanjay Rajagopalan, Stamatios Lerakis, Syed T Rahman, Sampath Parthasarathy, Bobby V Khan
- Durability of platelet inhibition by clopidogrel
- Paul A. Gurbel, Kevin P. Bliden
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?